M&A Deal Summary

Celgene Acquires Pharmion

On November 18, 2007, Celgene acquired life science company Pharmion for 2.9B USD

Acquisition Highlights
  • This is Celgene’s 2nd transaction in the Life Science sector.
  • This is Celgene’s 4th largest (disclosed) transaction.
  • This is Celgene’s 3rd transaction in the United States.
  • This is Celgene’s 2nd transaction in Colorado.

M&A Deal Summary
Date 2007-11-18
Target Pharmion
Sector Life Science
Buyer(s) Celgene
Deal Type Add-on Acquisition
Deal Value 2.9B USD
Advisor(s) BofA Securities (Financial)
Willkie Farr & Gallagher (Legal)

Target

Pharmion

Boulder, Colorado, United States
Pharmion Corporation is a global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza®, a DNA demethylating agent.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Celgene

Summit, New Jersey, United States
Category Company
Founded 1980
Sector Life Science
Employees6,971
Revenue 13.0B USD (2017)
DESCRIPTION

Celgene Corp. is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene Corp. was established in 1980 and is headquartered in Summit, New Jersey.

DEAL STATS #
Overall 4 of 15
Sector (Life Science) 2 of 12
Type (Add-on Acquisition) 3 of 13
State (Colorado) 2 of 2
Country (United States) 3 of 12
Year (2007) 1 of 1
Size (of disclosed) 4 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-04-26 Penn Pharmaceutical Services

Gwent, South Wales, United Kingdom

Penn Pharmaceutical Services Ltd. is a drug delivery business providing fully integrated pharmaceutical products and services.

Sell £67M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-12-07 Gloucester Pharmaceuticals

Cambridge, Massachusetts, United States

Gloucester develops cancer therapies including Istodax, which was approved by the Food and Drug Administration last month for treatment of cutaneous T-cell lymphoma patients who have had a least one prior systemic therapy. The treatment also has orphan drug designation for treatment of non-Hodgkin's T-cell lymphomas including CTCL and peripheral T-cell lymphoma, as well as fast-track status for PTCL.

Buy $640M
Mergr

Product

Company

Legal